Chi Sheng Pharma & Biotech Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Chi Sheng Pharma & Biotech.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	48.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Apr 06

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Mar 10

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Feb 01

Here's What You Should Know About Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) 4.2% Dividend Yield

Jan 05

Estimating The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Dec 10

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Chi Sheng Pharma & Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

TPEX:4111 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	1,104	71	83	175	N/A
6/30/2024	1,082	73	24	132	N/A
3/31/2024	1,065	73	-67	47	N/A
12/31/2023	1,061	69	-27	75	N/A
9/30/2023	1,090	116	9	111	N/A
6/30/2023	1,115	151	89	197	N/A
3/31/2023	1,130	164	107	225	N/A
12/31/2022	1,143	179	109	215	N/A
9/30/2022	1,105	186	128	216	N/A
6/30/2022	1,085	150	-73	197	N/A
3/31/2022	1,059	129	-100	164	N/A
12/31/2021	1,022	108	-126	139	N/A
9/30/2021	1,003	56	-137	125	N/A
6/30/2021	971	41	61	103	N/A
3/31/2021	953	46	87	109	N/A
12/31/2020	979	59	121	144	N/A
9/30/2020	1,005	72	101	129	N/A
6/30/2020	1,026	80	152	177	N/A
3/31/2020	1,047	85	179	206	N/A
12/31/2019	1,023	72	126	163	N/A
9/30/2019	998	57	131	187	N/A
6/30/2019	985	57	69	134	N/A
3/31/2019	964	46	18	87	N/A
12/31/2018	967	42	38	114	N/A
9/30/2018	985	52	34	98	N/A
6/30/2018	1,016	60	N/A	133	N/A
3/31/2018	1,032	69	N/A	157	N/A
12/31/2017	1,045	82	N/A	181	N/A
9/30/2017	1,034	91	N/A	162	N/A
6/30/2017	1,012	88	N/A	160	N/A
3/31/2017	995	85	N/A	133	N/A
12/31/2016	964	73	N/A	104	N/A
9/30/2016	946	48	N/A	130	N/A
6/30/2016	936	46	N/A	120	N/A
3/31/2016	938	42	N/A	116	N/A
12/31/2015	932	39	N/A	97	N/A
9/30/2015	908	40	N/A	92	N/A
6/30/2015	922	50	N/A	89	N/A
3/31/2015	925	59	N/A	116	N/A
12/31/2014	943	73	N/A	147	N/A
9/30/2014	979	104	N/A	167	N/A
6/30/2014	974	105	N/A	177	N/A
3/31/2014	960	106	N/A	188	N/A
12/31/2013	921	96	N/A	143	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4111's forecast earnings growth is above the savings rate (1.1%).

Earnings vs Market: Insufficient data to determine if 4111's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if 4111's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 4111's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 4111's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4111's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 12:10
End of Day Share Price	2024/12/24 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chi Sheng Pharma & Biotech Co., Ltd is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Li-chun Chang	Jih Sun Securities Investment Consulting Co., Ltd.
Xiaowei Huang	Masterlink Securities Corp.

Chi Sheng Pharma & Biotech Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.35 (vs NT$0.38 in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.36 (vs NT$0.36 in 2Q 2023)

Dividend reduced to NT$1.00

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 23%

Now 28% overvalued after recent price rise

First quarter 2024 earnings released: EPS: NT$0.41 (vs NT$0.33 in 1Q 2023)

Full year 2023 earnings released: EPS: NT$1.21 (vs NT$3.15 in FY 2022)

Chi Sheng Pharma & Biotech Co., Ltd, Annual General Meeting, Jun 13, 2024

New minor risk - Profit margin trend

Upcoming dividend of NT$1.20 per share at 4.5% yield

Second quarter 2023 earnings released: EPS: NT$0.36 (vs NT$0.46 in 2Q 2022)

Investor sentiment improves as stock rises 24%

Full year 2022 earnings released: EPS: NT$3.14 (vs NT$1.42 in FY 2021)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.00 per share

First quarter 2022 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS NT$0.39 (vs NT$0.14 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.21 (vs NT$0.28 in 2Q 2020)

Upcoming dividend of NT$1.00 per share

First quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.46 in 1Q 2020)

Read This Before Buying Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111) For Its Dividend

Full year 2020 earnings released: EPS NT$1.04 (vs NT$1.27 in FY 2019)

A Look At The Fair Value Of Chi Sheng Pharma & Biotech Co., Ltd (GTSM:4111)

Should Weakness in Chi Sheng Pharma & Biotech Co., Ltd's (GTSM:4111) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$22.80

New 90-day low: NT$23.30